Ocugen Enters Material Definitive Agreement

TL;DR

Ocugen signed a big deal, details to come.

AI Summary

Ocugen, Inc. entered into a Material Definitive Agreement on September 11, 2025. The filing does not disclose the specific nature or terms of this agreement, only its classification as material and definitive.

Why It Matters

This filing indicates a significant new contract or partnership for Ocugen, Inc., the details of which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — The lack of specific details about the material definitive agreement introduces uncertainty, making it a medium-risk event until more information is disclosed.

Key Players & Entities

• Ocugen, Inc. (company) — Registrant
• September 11, 2025 (date) — Date of earliest event reported
• 11 Great Valley Parkway Malvern, Pennsylvania 19355 (address) — Principal executive offices

FAQ

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 par value per share OCGN The Nasdaq
• $1 million — Agreement, the Company will receive (i) $1 million in upfront license fees; (ii) up to $6.
• $6.5 million — ion in upfront license fees; (ii) up to $6.5 million upon the achievement of certain regulat
• $1.5 million — ievement of certain sales milestones of $1.5 million for every $15 million of sales in the T
• $15 million — es milestones of $1.5 million for every $15 million of sales in the Territory. Additionally

Filing Documents

• tm2526167d1_8k.htm (8-K) — 28KB
• 0001104659-25-090113.txt ( ) — 190KB
• ocgn-20250911.xsd (EX-101.SCH) — 3KB
• ocgn-20250911_lab.xml (EX-101.LAB) — 33KB
• ocgn-20250911_pre.xml (EX-101.PRE) — 22KB
• tm2526167d1_8k_htm.xml (XML) — 3KB

01

Item 1.01. Entry Into a Material Definitive Agreement. On September 11, 2025, Ocugen, Inc. ("Ocugen" or the "Company"), entered into an Exclusive License Agreement (the "Agreement") with Kwangdong Pharmaceutical Co., Ltd. ("Kwangdong"), pursuant to which Kwangdong was granted an exclusive, non-sublicensable, royalty-bearing license to (i) import, export, distribute, use, have used, keep, sell, have sold, or offer for sale, including to research, develop, commercialize, register, modify, enhance, improve, or otherwise exploit OCU400 (the "licensed product")—Ocugen's novel modifier gene therapy for retinitis pigmentosa ("RP") in the Republic of Korea ("the Territory") and (ii) to use the trademark selected by Ocugen in the Territory solely in connection with OCU400 in gene therapy for the treatment of RP in humans. Kwangdong will have sole control over preparing, filing and maintaining regulatory submissions and communicating with regulatory authorities in the Territory. Kwangdong has agreed to use commercially reasonable efforts to develop, seek, register and obtain regulatory approval for the licensed product in the Territory. The Company will own the global safety database with respect to the licensed product. Under the Agreement, the Company will receive (i) $1 million in upfront license fees; (ii) up to $6.5 million upon the achievement of certain regulatory and development milestones; and (iii) payments upon achievement of certain sales milestones of $1.5 million for every $15 million of sales in the Territory. Additionally, Ocugen will receive a royalty of 25% on net sales of the licensed product generated by Kwangdong. Ocugen will manufacture the commercial supply of the licensed product under the terms of a supply agreement. The Agreement and the licenses granted thereunder, shall continue in force until the last to occur of: (a) the 20 year anniversary of the date of the first commercial sale of the licensed product in the Territory; (b) the expiration

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the anticipated benefits to Ocugen of the definitive license agreement, qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, which are subject to risks and uncertainties. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as, but not limited to, "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "anticipate," "project," "target," "design," "estimate," "predict," "potential," "plan," "on track," or similar expressions or the negative of those terms. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions, and uncertainties. The express or implied forward-looking statements included herein are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: the risks that the license agreement with Kwangdong will not lead to the current anticipated benefits to Ocugen, the risks that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; the ability of OCU400 to perform in humans in a manner consistent with nonclinical or preclinical study data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical da

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ocugen, Inc. Date: September 15, 2025 By: /s/ Shankar Musunuri Name: Shankar Musunuri Title: Chairman, Chief Executive Officer, & Co-Founder

View Full Filing

View this 8-K filing on SEC EDGAR